Kok, C.H.Al-Kali, A.Thomas, D.He, R.Kutyna, M.M.Alkhateeb, H.B.Lim, K.Saliba, A.N.Toop, C.Matin, A.Scott, H.S.Gangat, N.Brown, A.L.Mangaonkar, A.A.Hahn, C.N.Begna, K.Hung, K.Greipp, P.T.Hogan, W.J.Patnaik, M.M.et al.2025-10-152025-10-152025Blood advances, 2025; 9(15):3814-38182473-95292473-9537https://hdl.handle.net/2440/147791Research LetterAbstract not available.en© 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.RAS mutation; therapy-related myeloid neoplasmJournal article10.1182/bloodadvances.2025016374740354Kok, C.H. [0000-0002-3181-7852]Kutyna, M.M. [0000-0003-2315-091X]Lim, K. [0000-0003-4606-7588]Scott, H.S. [0000-0002-5813-631X]Brown, A.L. [0000-0002-9023-0138]Hahn, C.N. [0000-0001-5105-2554]Hiwase, D.K. [0000-0002-6666-3056]